Article

Extended-release pegaptanib injection under development

Eyetech Inc. has entered into a licensing and development agreement with SurModics Pharmaceuticals Inc. to develop an extended-release version of pegaptanib sodium injection (Macugen) using microparticle technology.

Palm Beach Gardens, FL-Eyetech Inc. has entered into a licensing and development agreement with SurModics Pharmaceuticals Inc. to develop an extended-release version of pegaptanib sodium injection (Macugen) using microparticle technology.

The drug, a selective inhibitor of vascular endothelial growth factor (VEGF)-165, is approved for the treatment of neovascular age-related macular degeneration (AMD). The goal of the extended-release formulation is to decrease the frequency of dosing from every 6 weeks to every 4 to 6 months.

“An extended-release formulation of [pegaptanib sodium injection] could offer several potential advantages to physicians, patients with neovascular AMD, and their families, including a more convenient dosing schedule, improved compliance, and a lower risk of complications related to the injection,” said Scott W. Cousins, MD, project leader for the Macugen Microparticles Program and vice chairman of research in the Department of Ophthalmology at Duke University School of Medicine, Durham, NC.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.